Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)

NCT02936635 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT02936635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02936635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Lead sponsor
Cytokinetics
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2016
Completion date
October 26, 2018
Enrollment
280 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)